Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARD), targeted synthetic DMARD (tsDMARD) and biosimilar DMARD (bsDMARD) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
Research Square (Research Square)